Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $60.2 million.

  • ImmunityBio's Cash & Equivalents fell 4619.71% to $60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.2 million, marking a year-over-year decrease of 4619.71%. This contributed to the annual value of $143.4 million for FY2024, which is 4596.86% down from last year.
  • Per ImmunityBio's latest filing, its Cash & Equivalents stood at $60.2 million for Q3 2025, which was down 4619.71% from $137.7 million recorded in Q2 2025.
  • ImmunityBio's Cash & Equivalents' 5-year high stood at $265.5 million during Q4 2023, with a 5-year trough of $36.4 million in Q1 2022.
  • Its 5-year average for Cash & Equivalents is $107.0 million, with a median of $104.2 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 41869.11% in 2021, then plummeted by 5440.3% in 2025.
  • ImmunityBio's Cash & Equivalents (Quarter) stood at $181.1 million in 2021, then plummeted by 42.22% to $104.6 million in 2022, then skyrocketed by 153.68% to $265.5 million in 2023, then plummeted by 45.97% to $143.4 million in 2024, then tumbled by 58.0% to $60.2 million in 2025.
  • Its Cash & Equivalents was $60.2 million in Q3 2025, compared to $137.7 million in Q2 2025 and $60.7 million in Q1 2025.